GlassScriptPhysician profile
Cedric K Olivera
NPI 1568638997
$790.21
in general payments reported to CMS, 2019-2025
12 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $46.74 · 2021: $17.11 · 2022: $318 · 2024: $72.78 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143 · Consulting Fee: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.67 |
| Consulting Fee | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon Endo-Surgery INC. | $250.00 | 2022 | |
| Coloplast Corp | $126.27 | 2019 | |
| Femselect INC. | $103.89 | 2025 | Enplace |
| Lupin INC. | $64.95 | 2019 | |
| Axonics, INC. | $53.97 | 2022 | |
| Ethicon INC. | $50.00 | 2024 | |
| Abbvie INC. | $46.74 | 2020 | |
| Daiichi Sankyo INC. | $24.34 | 2019 | |
| Astellas Pharma US INC | $22.78 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.11 | 2021 | |
| Escala Medical INC. | $16.00 | 2025 | |
| Boston Scientific Corporation | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cedric Olivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.